An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD — GALE  

Geographic Atrophy Secondary to Age-related Macular Degeneration Clinical Trial

Official title: A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Status Active, not recruiting

Clinical Trial Summary

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who participated in Study APL2-103 (NCT03777332) or completed the treatment at Month 24 of either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600).

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Atrophy
• Geographic Atrophy
• Geographic Atrophy Secondary to Age-related Macular Degeneration
• Macular Degeneration
• Neoplasm Metastasis

• NCT number: NCT04770545
• Study type: Interventional
• Source: Apellis Pharmaceuticals, Inc.
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: March 4, 2021
• Completion date: September 2025